Baseline characteristics of patients with psoriasis and the general population
| Variable | Psoriasis (n=78 630) | General population (n=5 983 338) | P values |
| Age (years) | <0.0001 | ||
| 10–39 years | 38 585 (49.1%) | 3 446 247 (57.6%) | |
| 40–90 years | 40 045 (50.9%) | 2 537 091 (42.4%) | |
| Sex | 0.529 | ||
| Females | 40 749 (51.8%) | 3 094 037 (51.7%) | |
| Obesity status (kg/m2) | <0.0001 | ||
| BMI<30 | 28 892 (36.7%) | 2 502 902 (41.8%) | |
| BMI≥30 | 6497 (8.3%) | 433 773 (7.2%) | |
| Missing | 43 241 (55.0%) | 3 046 663 (50.9%) | |
| Smoking status | <0.0001 | ||
| Current | 19 455 (24.7%) | 1 204 834 (20.1%) | |
| Ex-smoker | 7384 (9.4%) | 540 987 (9.0%) | |
| Never | 34 876 (44.4%) | 2 996 546 (50.1%) | |
| Missing | 16 915 (21.5%) | 1 240 971 (20.7%) | |
| Alcohol use | <0.0001 | ||
| User | 31 598 (40.2%) | 2 634 769 (44.0%) | |
| Non-user | 14 949 (19.0%) | 1 033 560 (17.3%) | |
| Missing | 32 083 (40.8%) | 2 315 009 (38.7%) | |
| Charlson Comorbidity Index* | <0.0001 | ||
| 0 | 62 609 (79.6%) | 4 817 790 (80.5%) | |
| 1 | 11 258 (14.3%) | 754 495 (12.6%) | |
| 2 | 2238 (2.8%) | 165 226 (2.8%) | |
| 3 | 813 (1.0%) | 62 700 (1.0%) | |
| ≥4 | 1712 (2.2%) | 183 127 (3.1%) | |
| Townsend Deprivation Index† | <0.0001 | ||
| 1 | 18 438 (23.4%) | 1 289 151 (21.5%) | |
| 2 | 16 178 (20.6%) | 1 147 462 (19.2%) | |
| 3 | 15 616 (19.9%) | 1 157 934 (19.4%) | |
| 4 | 14 224 (18.1%) | 1 103 255 (18.4%) | |
| 5 | 10 144 (12.9%) | 802 761 (13.4%) | |
| Missing | 4030 (5.1%) | 482 775 (8.1%) | |
| Systemic psoriasis therapy | <0.0001 | ||
| User | 3191 (4.1%) | 50 172 (0.8%) | |
| Systemic steroid use | <0.0001 | ||
| User | 19 738 (25.1%) | 748 707 (12.5%) | |
| Fluoroquinolone use | <0.0001 | ||
| User | 12 445 (15.8%) | 480 857 (8.0%) |
Values show the number (%) of patients with a given characteristic. Moderate–severe psoriasis defined based on therapy use (see Methods section).
*Higher=more comorbidities.
†Higher=more socially deprived.